Abstract
BackgroundIncreasing evidences supported the association between long non-coding RNA (lncRNA) and disease free survival in gastric cancer (GC) patients. The purpose of the current study was to construct and verify a noninvasive preoperative predictive tool for disease free survival in GC patients.MethodsThere were 265 and 300 GC patients in model dataset and validation dataset respectively. The associations between the lncRNA biomarkers and disease free survival were evaluated by univariate and multivariate Cox regression.ResultsThirteen lncRNA biomarkers (GAS5-AS1, AL109615.3, KDM7A-DT, AP000866.2, KCNJ2-AS1, LINC00656, LINC01777, AC046185.3, TTTY14, LINC01526, LINC02523, LINC00592, and C5orf66) were identified as prognostic biomarkers with disease free survival. These thirteen lncRNA biomarkers were combined to construct a prognostic signature for disease free survival. The C-indexes of the current predictive signature in model cohort were 0.849 (95% CI 0.803–0.895), 0.859 (95% CI 0.813–0.905) and 0.888 (95% CI 0.842–0.934) for 1-year, 3-year and 5-year disease free survival respectively. Based on thirteen-lncRNA prognostic signature, patients in model cohort could be stratified into high risk group and low risk group with significant different disease free survival rate (hazard ratio [HR] = 7.355, 95% confidence interval [CI] 4.378–12.356). Good reproducibility of thirteen-lncRNA prognostic signature was confirmed in an external validation cohort (GSE62254) with HR 3.919 and 95% CI 2.817–5.453. Further analysis demonstrated that the prognostic significance of thirteen-lncRNA prognostic signature was independent of other clinical characteristics.ConclusionsIn conclusion, a simple noninvasive prognostic signature was established for preoperative prediction of disease free survival in GC patients. This prognostic signature might predict the individual mortality risk of disease free survival without pathological information and facilitate individual treatment decision-making.
Highlights
As a serious challenge to public health, gastric cancer (GC) is the fifth most common cancer and the third leading cause for cancer associated mortality in the world [1]
Protocol approval The study datasets in the current study were obtained from The Cancer Genome Atlas (TCGA) database and the Gene Expression Omnibus (GEO) database
The current study developed and validated a thirteen-long non-coding RNA (lncRNA) prognosis signature for prognostic prediction of GC patients
Summary
As a serious challenge to public health, gastric cancer (GC) is the fifth most common cancer and the third leading cause for cancer associated mortality in the world [1]. The TNM stage system of the American Joint Committee on Cancer (AJCC) was insufficient for prognostic prediction of GC patients [4, 5]. Increasing evidences demonstrated that the molecular biomarkers were helpful for improvement of prognostic prediction and early identification of GC patients with high mortality risk [6,7,8]. It is necessary to develop a valuable preoperative prognostic signature to identify GC patients with high mortality risk and improve the clinical treatment decision. Increasing evidences supported the association between long non-coding RNA (lncRNA) and disease free survival in gastric cancer (GC) patients. The purpose of the current study was to construct and verify a noninvasive preoperative predictive tool for disease free survival in GC patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
